Chin Kim, MD
Interventional Cardiology · Orlando, FLNPI 1437120896
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $103 of the $115 with a category attached, or 89.2%. Medtronic accounts for 75.4% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.
Across 3 payments — averaging $38.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$87
- Daiichi Sankyo Inc.$16
- Regeneron Healthcare Solutions, Inc.$12
Across 2 payments — averaging $4250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$9K
What the payments were for
- Food & beverage$10389%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $87 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
How this compares
$115 in reported general payments places this provider in the 0th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $367,312 |
| XareltoRivaroxaban | 35 | $53,149 |
| EntrestoSacubitril/Valsartan | 26 | $29,865 |
| MultaqDronedarone Hcl | 15 | $25,491 |
| Repatha SureclickEvolocumab | 26 | $24,149 |
| Rosuvastatin Calcium | 467 | $6,189 |
| Ranolazine ErRanolazine | 28 | $3,284 |
| Metoprolol Succinate | 267 | $3,223 |
| ClopidogrelClopidogrel Bisulfate | 188 | $2,524 |
| Atorvastatin Calcium | 262 | $2,304 |
| Ezetimibe | 92 | $2,042 |
| Losartan Potassium | 163 | $1,938 |
| Carvedilol | 170 | $1,681 |
| Potassium Chloride | 39 | $1,271 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 106 | $1,261 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Orlando
- Zahid AminOrlando$635K
- Bruce SteinOrlando$151K
- Aalok PatelOrlando$115K
- Vijaykumar KasiOrlando$77K
- Farhan KhawajaOrlando$77K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Rohit AminPensacola$560K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.